EVALUATING NON-AIDS INFECTIOUS DISEASE CONTROL MEASURES

本合同的总体目标是评估控制措施 艾滋病以外的传染病。仍有许多传染性疾病 有效和高度安全的疫苗和治疗方法所针对的疾病 还有待开发。此外，对于某些疾病，改进的疫苗是 需要预防感染和疾病的年龄段目前不是 保护，这将提供更高的安全性。新型疫苗和药物 在基础知识进步的推动下，候选人继续得到发展 科学。评估这些新的和改进的疫苗的能力和 以高效和快速的方式接受治疗是必不可少的 微生物学和感染科的工作内容 国家过敏症和传染病研究所的疾病(DMID) 疾病(NIAID)。这份疫苗和治疗评估合同 单位[VTEU]是这些努力的组成部分，并支持第一阶段和 细菌和病毒疫苗的第二阶段临床试验，其他 生物制品和药物作为预防和治疗措施 传染病在所有年龄段和风险类别的人中。在所选项目中 在某些情况下，也可以进行第三阶段疫苗试验。也可以是 重要的是对符合以下条件的病原体进行流行病学监测 对NIAID的特殊兴趣，以及进行有限的、相关的、 基础和临床前研究直接与疫苗生物学和 免疫学。

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). This contract for a Vaccine and Treatment Evaluation Unit [VTEU] is an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.